A high-fat diet induces bone loss in mice lacking the Alox5 gene

Endocrinology

Volumn 153, Issue 1, 2012, Pages 6-16

  Le, Phuong ^a   Kawai, Masanobu ^a,b   Bornstein, Sheila ^a   DeMambro, Victoria E ^a   Horowitz, Mark C ^c   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United States)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CARBOXY TERMINAL TELOPEPTIDE; CELECOXIB; CYCLOOXYGENASE 2; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE STRUCTURE; BONE TURNOVER; CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GENE EXPRESSION; GENOTYPE ENVIRONMENT INTERACTION; LIPID DIET; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL; TRABECULAR BONE; WILD TYPE;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BONE DENSITY; BONE RESORPTION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIET, HIGH-FAT; FEMALE; GENE EXPRESSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; OSTEOCLASTS; PPAR GAMMA; PYRAZOLES; SULFONAMIDES;

EID: 84455188718     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-0082     Document Type: Article

References (49)

1. McCarthy MI 2010 Genomics, type 2 diabetes, and obesity. N Engl J Med 363:2339-2350
2. Kawai M, Rosen CJ Bone 2010 adiposity and bone accrual-still an established paradigm? Nat Rev Endocrinol 6:63-64
3. von Muhlen D, Safii S, Jassal SK, Svartberg J, Barrett-Connor E 2007 Associations between the metabolic syndrome and bone health in older men and women: the rancho Bernardo study. Osteoporos Int 18:1337-1344 (Pubitemid 47389466)
4. Goulding A, Taylor RW, Grant AM, Jones S, Taylor BJ, Williams SM 2009 Relationships of appendicular LMI and total body LMI to bone mass and physical activity levels in a birth cohort of New Zealand five-year olds. Bone 45:455-459
5. Dimitri P, Wales JK, Bishop N 2010 Fat and bone in children: differential effects of obesity on bone size and mass according to fracture history. J Bone Miner Res 25:527-536
6. Janicka A, Wren TA, Sanchez MM, Dorey F, Kim PS, Mittelman SD, Gilsanz V 2007 Fat mass is not beneficial to bone in adolescents and young adults. J Clin Endocrinol Metab 92:143-147 (Pubitemid 46075009)
7. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L 2010 Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 6:71-8
8. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M 2004 Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350:29-37 (Pubitemid 38032181)
9. Williams ES, Baylin A, Campos H 2007 Adipose tissue arachidonic acid and the metabolic syndrome in Costa Rican adults. Clin Nutr 26:474-482 (Pubitemid 47091481)
10. Garaulet M, Pérez-Llamas F, Pérez-Ayala M, Martínez P, de Medina FS, Tebar FJ, Zamora S 2001 Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterraneanarea: relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr 74:585-591
11. Decsi T, Molnár D, Koletzko B 1996 Long-chain polyunsaturated fatty acids in plasma lipids of obese children. Lipids 31:305-311 (Pubitemid 26094308)
12. Samuelsson B 1983 Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-575 (Pubitemid 13130140)
13. Peters-Golden M, Henderson Jr WR 2007 Leukotrienes. N Engl J Med 357:1841-1854
14. Rådmark O, Samuelsson B 2010 Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem Biophys Res Commun 396:105-110
15. Allayee H, Baylin A, Hartiala J, Wijesuriya H, Mehrabian M, Lusis AJ, Campos H 2008 Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction. Am J Clin Nutr 88:934-940
16. Mehrabian M, Allayee H, Stockton J, Lum PY, Drake TA, Castellani LW, Suh M, Armour C, Edwards S, Lamb J, Lusis AJ, Schadt EE 2005 Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 37:1224-1233 (Pubitemid 41568705)
17. Kawai M, Sousa KM, MacDougald OA, Rosen CJ 2010 The many facets of PPARγ: novel insights for the skeleton. Am J Physiol Endocrinol Metab 299:E3-E9
18. Kawai M, Rosen CJ 2010 PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 6:629-636
19. Tontonoz P, Spiegelman BM 2008 Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 77:289-312
20. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM 1994 mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234
21. Rosen ED, MacDougald OA 2006 Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7:885-896 (Pubitemid 44871415)
22. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855 (Pubitemid 38544143)
23. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B 2004 Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell 3:379-389 (Pubitemid 40246708)
24. Lecka-Czernik B, Rosen CJ, Kawai M 2010 Skeletal aging and the adipocyte program: new insights from an "old" molecule. Cell Cycle 9:3648-3654
25. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK 2010 Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95:592-600
26. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR 2007 The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310 (Pubitemid 46556402)
27. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-≲δλτα∀ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812 (Pubitemid 3006324)
28. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA 2003 Biosynthesis of 15-deoxy-δ 12,14-PGJ2 and the ligation of PPARγ. J Clin Invest 112:945-955 (Pubitemid 38063752)
29. Kwak HJ, Park KM, Choi HE, Lim HJ, Park JH, Park HY 2010 The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKCδ. Cell Signal 22:80-87
30. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL 2001 Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 15:2007-2009
31. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ 2008 Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 149:2051-2061 (Pubitemid 351574504)
32. Delahunty KM, Shultz KL, Gronowicz GA, Koczon-Jaremko B, Adamo ML, Horton LG, Lorenzo J, Donahue LR, Ackert-Bicknell C, Kream BE, Beamer WG, Rosen CJ 2006 Congenic mice provide in vivo evidence for a genetic locus that modulates serum insulin-like growth factor-I and bone acquisition. Endocrinology 147:3915-3923 (Pubitemid 44079397)
33. Beamer WG, Shultz KL, Ackert-Bicknell CL, Horton LG, Delahunty KM, Coombs HF 3rd, Donahue LR, Canalis E, Rosen CJ 2007 Genetic dissection of mouse distal chromosome 1 reveals three linked BMD QTLs with sex-dependent regulation of bone phenotypes. J Bone Miner Res 22:1187-1196 (Pubitemid 351339701)
34. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595-610
35. Kawai M, Green CB, Lecka-Czernik B, Douris N, Gilbert MR, Kojima S, Ackert-Bicknell C, Garg N, Horowitz MC, Adamo ML, Clemmons DR, Rosen CJ 2010 A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-γ nuclear translocation. Proc Natl Acad Sci USA 107:10508-10513
36. Ackert-Bicknell CL, Demissie S, Marín de Evsikova C, Hsu YH, DeMambro VE, Karasik D, Cupples LA, Ordovas JM, Tucker KL, Cho K, Canalis E, Paigen B, Churchill GA, Forejt J, Beamer WG, Ferrari S, Bouxsein ML, Kiel DP, Rosen CJ 2008 PPARG by dietary fat interaction influences bone mass in mice and humans. J Bone Miner Res 23:1398-1408
37. Cao JJ, Gregoire BR, Gao H 2009 High-fat diet decreases cancellous bone mass but has no effect on cortical bone mass in the tibia in mice. Bone 44:1097-1104
38. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520 (Pubitemid 40477060)
39. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317 (Pubitemid 35345151)
40. Kawai M, Devlin MJ, Rosen CJ 2009 Fat targets for skeletal health. Nat Rev Rheumatol 5:365-372
41. Manolagas SC 2010 From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31:266-300
42. Blackwell KA, Raisz LG, Pilbeam CC 2010 Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 21:294-301
43. Tian XY, Zhang Q, Zhao R, Setterberg RB, Zeng QQ, Iturria SJ, Ma YF, Jee WS 2008 Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats. Bone 42:914-920
44. Koshihara Y, Kawamura M 1989 Prostaglandin D2 stimulates calcification of human osteoblastic cells. Biochem Biophys Res Commun 159:1206-1212 (Pubitemid 19101111)
45. Takagi T, Yamamoto T, Asano S, Tamaki H 1993 Effect of prostaglandin D2 on the femoral bone mineral density in ovariectomized rats. Calcif Tissue Int 52:442-446 (Pubitemid 23155367)
46. Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, Rosen CJ 2009 Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology 150:1330-1340
47. Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Beamer WG, Sipos J, Clemmons D, Nelson T, Bouxsein ML, Horowitz M 2004 Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 35:1046-1058 (Pubitemid 39487350)
48. Wan Y, Chong LW, Evans RM 2007 PPAR-γ regulates osteoclastogenesis in mice. Nat Med 13:1496-1503
49. Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM, Wan Y 2010 PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11:503-516